---
figid: PMC8696218__CAC2-41-1275-g001
figtitle: Emerging agents that target signaling pathways to eradicate colorectal cancer
  stem cells
organisms:
- Lareunionomyces loeiensis
- herbal medicine
- Panax ginseng
- Curcuma longa
- Allium sativum
- Scutellaria baicalensis
- Citrus x paradisi
- Silybum marianum
- Polygonum cuspidatum
- Momordica charantia
- Garcinia mangostana
- Atractylodes macrocephala
- Tanacetum parthenium
- Tetradium ruticarpum
- Portulaca oleracea
- Bertholletia excelsa
- Escherichia coli
- Streptomyces hygroscopicus
- Streptomyces albus
- Mus musculus
- Rattus norvegicus
- Adenoviridae
- Rat sarcoma virus
- Homo sapiens
- Paraechinus aethiopicus
- NA
pmcid: PMC8696218
filename: CAC2-41-1275-g001.jpg
figlink: /pmc/articles/PMC8696218/figure/cac212235-fig-0004/
number: F4
caption: 'The NF‐κB signaling pathway. In the canonical pathway, the inhibitory protein
  IκB inhibits the translocation of the p65/p50 and c‐Rel/p50 dimers to the cell nucleus.
  The ubiquitination of IκB and its subsequent degradation release these proteins
  to be translocated to the cell nucleus, leading to the activation of the target
  genes. In the non‐canonical pathway, NIK induces the ubiquitination of p100 and
  its subsequent processing by proteasomes in p52. Then, RelB/p52 is translocated
  to the cell nucleus to activate the target genes. Abbreviations: ABL, ABL proto‐oncogene
  1, non‐receptor tyrosine kinase; BAFF, B cell‐activating factor; BCR, BCR activator
  of RhoGEF and GTPase; BMP‐2, bone morphogenetic protein‐2; CCL19, C‐C motif chemokine
  ligand 19; CIAP1, cellular inhibitor of apoptosis protein 1; ICAM1, intercellular
  adhesion molecule 1; IKK, inhibitor of NF‐κB kinase; IκB, inhibitor of NF‐κB; Kras,
  Kirsten rat sarcoma viral oncogene homolog; LPS, lipopolysaccharide; LTβR, lymphotoxin
  beta receptor; MMP9, matrix metalloproteinase 9; MYC, MYC proto‐oncogene, bHLH transcription
  factor; NF‐κB, nuclear factor kappa B; NIK, NF‐κB‐inducing kinase; RANK, receptor
  activator of NF‐κB; TERT, telomerase reverse transcriptase; TNF, tumor necrosis
  factor'
papertitle: Emerging agents that target signaling pathways to eradicate colorectal
  cancer stem cells.
reftext: Valdenizia R. Silva, et al. Cancer Commun (Lond). 2021 Dec;41(12):1275-1313.
year: '2021'
doi: 10.1002/cac2.12235
journal_title: Cancer Communications
journal_nlm_ta: Cancer Commun (Lond)
publisher_name: John Wiley and Sons Inc.
keywords: colorectal | cancer stem cells | cell signaling | Wnt/β‐catenin pathway
  | Notch | Hedgehog | NF‐κB | JAK/STAT signaling | PI3K/Akt/mTOR signaling | targeted
  therapy
automl_pathway: 0.9405848
figid_alias: PMC8696218__F4
figtype: Figure
organisms_ner:
- Rattus norvegicus
- Homo sapiens
- Mus musculus
redirect_from: /figures/PMC8696218__F4
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8696218__CAC2-41-1275-g001.html
  '@type': Dataset
  description: 'The NF‐κB signaling pathway. In the canonical pathway, the inhibitory
    protein IκB inhibits the translocation of the p65/p50 and c‐Rel/p50 dimers to
    the cell nucleus. The ubiquitination of IκB and its subsequent degradation release
    these proteins to be translocated to the cell nucleus, leading to the activation
    of the target genes. In the non‐canonical pathway, NIK induces the ubiquitination
    of p100 and its subsequent processing by proteasomes in p52. Then, RelB/p52 is
    translocated to the cell nucleus to activate the target genes. Abbreviations:
    ABL, ABL proto‐oncogene 1, non‐receptor tyrosine kinase; BAFF, B cell‐activating
    factor; BCR, BCR activator of RhoGEF and GTPase; BMP‐2, bone morphogenetic protein‐2;
    CCL19, C‐C motif chemokine ligand 19; CIAP1, cellular inhibitor of apoptosis protein
    1; ICAM1, intercellular adhesion molecule 1; IKK, inhibitor of NF‐κB kinase; IκB,
    inhibitor of NF‐κB; Kras, Kirsten rat sarcoma viral oncogene homolog; LPS, lipopolysaccharide;
    LTβR, lymphotoxin beta receptor; MMP9, matrix metalloproteinase 9; MYC, MYC proto‐oncogene,
    bHLH transcription factor; NF‐κB, nuclear factor kappa B; NIK, NF‐κB‐inducing
    kinase; RANK, receptor activator of NF‐κB; TERT, telomerase reverse transcriptase;
    TNF, tumor necrosis factor'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Myc
  - Ccnd1
  - Bmp2
  - Bcl2
  - Tnf
  - Mmp9
  - Il13
  - Kras
  - Syt1
  - Nfkb1
  - Ltbr
  - Cd40
  - Tnfsf11
  - Tnfsf13b
  - Relb
  - App
  - Tert
  - Il9
  - Ccl19
  - Icam1
  - MYC
  - CCND1
  - BMP2
  - BCL2
  - TNF
  - MMP9
  - IRF6
  - IL13
  - KRAS
  - NRAS
  - ABL1
  - IKBKG
  - CHUK
  - IKBKB
  - IKBKE
  - TBK1
  - RELA
  - SYT1
  - GORASP1
  - WNK1
  - CD40
  - ARHGEF7
  - ASCC1
  - H3P40
  - NFKB1
  - LTBR
  - TNFSF11
  - TNFSF13B
  - RELB
  - FKBP4
  - GTF2H4
  - NFKB2
  - PMPCB
  - PSIP1
  - H3P42
  - MAP3K14
  - MAP4K4
  - APP
  - SUCLA2
  - CUX1
  - OAS3
  - PMEL
  - SART3
  - TPX2
  - SND1
  - ASCC2
  - TERT
  - CXCL8
  - IL9
  - CCL19
  - ICAM1
  - BIRC2
  - Nol3
  - Bmpr2
  - Tlr4
  - Nfkbib
  - Rela
  - Gorasp1
  - Cdc37
  - Lsp1
  - Pold2
  - Dctn2
  - Gtf2h4
  - Nfkb2
  - Igbp1
  - Map4k4
  - Map3k14
  - H2-Ab1
  - Tpx2
  - Cxcl15
  - Birc3
  - Birc2
---
